Table 1.

Selected characteristics of participants at baseline and of those who did not return

CharacteristicsBaseline (N =69), n (%)Women still eligible* who did not return (N = 18), n (%)Two-sided P
Age (y)46.6 (SD, 7.9)45.7 (SD, 8.0)0.67
Ethnicity
    Caucasian66 (95.7)18 (100.0)
    African American3 (4.3)1.00
Marital status
    Single3 (4.3)1 (5.6)
    Married65 (94.2)17 (94.4)1.00
    Missing1 (1.4)
Education
    ≤High school4 (5.8)
    College38 (55.1)12 (66.7)
    Postgraduate27 (39.1)6 (33.3)0.59
Cigarette smoking
    Never47 (68.1)15 (83.3)
    Former18 (26.1)3 (16.7)0.55
    Current4 (5.8)
Body mass index
    <2534 (49.3)7 (38.9)
    ≥2534 (49.3)11 (61.1)0.56
    Missing1 (1.4)
Oral contraceptive
    Never15 (21.7)3 (16.7)
    Former40 (58.0)11 (61.1)
    Current12 (17.4)4 (22.2)0.88
    Missing2 (2.9)
Hormone replacement
    Never42 (60.9)11 (61.1)
    Former16 (23.2)5 (27.8)
    Current5 (7.2)1 (5.6)
    Missing6 (8.7)1 (5.6)0.97
Age at menarche (y)
    <1217 (24.6)5 (27.8)
    ≥1249 (71.0)13 (72.2)
    Missing3 (4.4)1.00
Menopausal status
    Premenopausal41 (59.4)9 (50.0)
    Postmenopausal28 (40.6)9 (50.0)0.59
Mean age at 1st
birth (y)27.8 (SD, 5.7)28.7 (SD, 5.5)0.55
Breast-feeding
    No29 (42.0)6 (33.3)
    Yes38 (55.1)11 (61.1)
    Missing2 (2.9)1 (5.6)0.48
Parity
    Nulliparous18 (26.1)3 (16.7)
    Parous51 (73.9)15 (83.3)0.54
Family history breast cancer
    No16 (23.2)4 (22.2)
    Yes53 (76.8)14 (77.8)1.00
Gail 5-y risk ++
    <1.6620 (29.0)7 (38.9)
    ≥1.6638 (55.1)8 (44.4)
    N/A11 (15.9)3 (16.7)0.63
Genetic testing
    No55 (79.7)11 (61.1)
    Yes14 (20.3)7 (38.9)
        BRCA mutation carrier200.13
Prophylactic oophorectomy8 (12.1)2 (11.1)1.00
Breast biopsies
    Never31 (44.9)12 (66.7)
    119 (27.5)4 (22.2)
    >119 (27.5)2 (11.1)0.22
Abnormal breast biopsies
    No49 (71.0)15 (83.3)
    Yes (atypia, LCIS, DCIS, invasive breast cancer)20 (29.0)3 (16.7)0.38
Prior breast cancer (DCIS/invasive breast cancer)11 (15.9)3 (16.7)1.00
Treatment for breast cancer
    None62 (89.9)17 (94.4)
    Chemotherapy alone1 (1.4)1 (5.6)
    Radiation alone2 (2.9)
    Radiation/chemotherapy4 (5.8)0.51
SERMS
    Never43 (62.3)10 (55.6)
    Former12 (17.4)4 (22.2)
    Current8 (11.6)2 (11.1)
    Don't know/missing6 (8.7)2 (11.1)0.92
  • NOTE: P values were determined by t test for continuous variables and by χ2 test for categorical variables. The Fisher exact test was used when there were <10 observations per category.

    Abbreviations: SERMS, selective estrogen receptor modulators; LCIS, lobular carcinoma in situ; DCIS, ductal carcinoma in situ.

  • * Four women were ineligible to return; one woman had a bilateral mastectomy, another had surgery for a benign breast lump, the third was pregnant, and a fourth developed erythema that persisted for 1 wk post lavage. Gail 5-y risk was calculated from National Cancer Institute Gail model (http://bcra.nci.nih.gov/brc/q1.htm).